Polo-like kinase 1 (PLK1) is a serine/threonine kinase with more than 600 phosphorylation substrates through which it regulates many biological processes, including mitosis, apoptosis, metabolism, RNA processing, vesicle transport, and G DNA-damage checkpoint recovery, among others. Among the many PLK1 targets are members of the FOX family of transcription factors (FOX TFs), including FOXM1, FOXO1, FOXO3, and FOXK1. FOXM1 and FOXK1 have critical oncogenic roles in cancer through their antagonism of apoptotic signals and their promotion of cell proliferation, metastasis, angiogenesis, and therapeutic resistance. In contrast, FOXO1 and FOXO3 have been identified to have broad functions in maintaining cellular homeostasis. In this review, we discuss PLK1-mediated regulation of FOX TFs, highlighting the effects of PLK1 on the activity and stability of these proteins. In addition, we review the prognostic and clinical significance of these proteins in human cancers and, more importantly, the different approaches that have been used to disrupt PLK1 and FOX TF-mediated signaling networks. Furthermore, we discuss the therapeutic potential of targeting PLK1-regulated FOX TFs in human cancers.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177174 | PMC |
| http://dx.doi.org/10.3390/cells12091344 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genome-Wide Expression Profiling and Phenotypic Analysis of Downstream Targets Identify the Fox Transcription Factor Jumeau as a Master Regulator of Cardiac Progenitor Cell Division.
Int J Mol Sci
December 2024
Department of Biology, Indiana State University, Terre Haute, IN 47809, USA.
Article Synopsis
- - Forkhead box (Fox) transcription factors (TFs) are crucial for heart development in mammals, influencing cardiac progenitor cell roles and positions.
- - Researchers found that the Jumu gene plays a key regulatory role, with many downstream targets linked to cell division in cardiac progenitor cells.
- - The study highlights Jumu as a central hub in a network that controls cardiac progenitor cell division, supported by the interactions of identified gene targets.
Comparative transcriptomic analysis uncovers molecular heterogeneity in hepatobiliary cancers.
Transl Oncol
January 2025
Department of Molecular Biology and Biotechnology, Tezpur University, Napaam, Sonitpur, Assam, 784028, India. Electronic address:
Hepatobiliary cancers (HBCs) pose a major global health challenge, with a lack of effective targeted biomarkers. Due to their complex anatomical locations, shared risk factors, and the limitations of targeted therapies, generalized treatment strategies are often used for gallbladder cancer (GBC), hepatocellular carcinoma (HCC), and intrahepatic cholangiocarcinoma (ICC). This study aimed to identify specific transcriptomic signatures in GBC, HCC, and ICC.
View Article and Find Full Text PDFTreatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214.
J Immunother Cancer
July 2024
Harvard Medical School, Boston, Massachussetts, USA.
Article Synopsis
- Immunotherapy, like the combination of nivolumab and ipilimumab (NIVO+IPI), can lead to prolonged disease control and treatment-free survival (TFS) for cancer patients, even after stopping treatment, which is not accounted for by standard survival measures.
- A study analyzed data from 1,096 advanced renal cell carcinoma patients to estimate TFS, comparing those treated with NIVO+IPI against sunitinib (SUN), focusing on both survival time and treatment-related adverse events (TRAEs).
- Results showed that 48% of patients on NIVO+IPI were alive after 5 years, with a significant difference in mean TFS compared to SUN, particularly in favorable-risk patients, highlighting the importance of considering
The Role of FOXA1 in Human Normal Development and Its Functions in Sex Hormone-Related Cancers.
Front Biosci (Landmark Ed)
June 2024
Hainan Provincial Key Laboratory for Human Reproductive Medicine and Genetic Research & Key Laboratory of Reproductive Health Diseases Research and Translation, Ministry of Education & Hainan Provincial Clinical Research Center for Thalassemia, Department of Reproductive Medicine, National Center for International Research "China-Myanmar Joint Research Center for Prevention and Treatment of Regional Major Disease" by the Ministry of Science and Technology of China, Haikou Key Laboratory for Preservation of Human Genetic Resource, The First Affiliated Hospital of Hainan Medical University, Hainan Medical University, 571101 Haikou, Hainan, China.
Article Synopsis
- * The FOXA subfamily, which includes FOXA1, FOXA2, and FOXA3, is crucial for mammalian development, particularly FOXA1, which is expressed in various tissues and influences cell proliferation and differentiation.
- * FOXA1 also plays an important role in the development of sex hormone-related tumors, making it a key player in cancer biology, especially in breast and prostate cancer.
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).
J Immunother Cancer
April 2024
Biostatistics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Background: As part of a partitioned survival analysis, treatment-free survival (TFS) can characterize the overall survival time patients spend between the cessation of immunotherapy and the start of subsequent therapy; both with and without toxicity. Significant TFS was reported for the nivolumab/ipilimumab arms of the CheckMate 067 and 214 trials for patients with advanced melanoma or renal cell carcinoma (aRCC), respectively, where immunotherapy was often halted for toxicity rather than a predefined treatment endpoint. We therefore sought to assess TFS in the HCRN GU16-260 trial, which was designed to reduce toxicity and cap immunotherapy duration.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!